Hansa Biopharma: Imlifidase continues to deliver improved sales in early 2024 - Redeye

Hansa’s preliminary Q1 result suggests that Idefirix records European product sales of SEK 48 (43m in Q4) in Q1. In Q1, Hansa received support from countries like the UK, France, Germany, and Belgium. This is the second consecutive quarter with improved sales compared with the earlier rolling 12m level.

Länk till analysen i sin helhet: https://www.redeye.se/research/993244/hansa-biopharma-imlifidase-continues-to-deliver-improved-sales-in-early-2024?utm_source=finwire&utm_medium=RSS